Autolus Therapeutics plc Basic Shares Outstanding (Weighted Average)
Autolus Therapeutics plc (AUTL) reported Basic Shares Outstanding (Weighted Average) of 266.16 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 266.16M shares, a 0.01% increase year-over-year.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 266.14M shares, a 0.01% increase year-over-year.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 266.14M shares, a 0.02% decline year-over-year.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 266.14M shares, a 0.02% increase year-over-year.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2025 was 266.14M shares, a 4.30% increase from fiscal 2024.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2024 was 255.16M shares, a 46.69% increase from fiscal 2023.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2023 was 173.94M shares, a 83.11% increase from fiscal 2022.
- Autolus Therapeutics plc weighted average number of shares outstanding, basic for fiscal 2022 was 94.99M shares, a 31.78% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 266.16M shares 10-Q · filed 2026-08-11 | 266.15M shares 10-Q · filed 2026-08-11 | 266.15M shares derived: average of 3 quarters · filed 2026-08-11 | 266.15M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 266.14M shares 10-Q · filed 2026-05-14 | 266.14M shares derived: average of 2 quarters · filed 2026-05-14 | 266.14M shares derived: average of 3 quarters · filed 2026-05-14 | 266.14M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 266.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 266.14M shares derived: average of 2 quarters · filed 2026-03-27 | 266.14M shares derived: average of 3 quarters · filed 2026-08-11 | 266.14M shares 10-K · filed 2026-03-27 |
| 2025-09-30 | 266.14M shares 10-Q · filed 2025-11-12 | 266.14M shares derived: average of 2 quarters · filed 2026-08-11 | 266.14M shares 10-Q · filed 2025-11-12 | 266.15M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 266.14M shares 10-Q · filed 2026-08-11 | 266.13M shares 10-Q · filed 2026-08-11 | 266.16M shares derived: average of 3 quarters · filed 2026-08-11 | 266.14M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 266.13M shares 10-Q · filed 2026-05-14 | 266.16M shares derived: average of 2 quarters · filed 2026-05-14 | 266.14M shares derived: average of 3 quarters · filed 2026-05-14 | 266.11M shares derived: average of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | 266.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | 266.14M shares derived: average of 2 quarters · filed 2026-03-27 | 266.10M shares derived: average of 3 quarters · filed 2026-03-27 | 255.16M shares 10-K · filed 2026-03-27 |
| 2024-09-30 | 266.08M shares 10-Q · filed 2025-11-12 | 266.06M shares derived: average of 2 quarters · filed 2025-11-12 | 251.48M shares 10-Q · filed 2025-11-12 | 232.09M shares derived: average of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | 266.03M shares 10-Q · filed 2025-08-12 | 255.13M shares 10-Q · filed 2025-08-12 | 220.76M shares derived: average of 3 quarters · filed 2025-08-12 | 209.07M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 222.17M shares 10-Q · filed 2025-05-08 | 198.13M shares derived: average of 2 quarters · filed 2025-05-08 | 190.08M shares derived: average of 3 quarters · filed 2025-05-08 | 186.03M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 174.10M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 174.04M shares derived: average of 2 quarters · filed 2025-03-20 | 173.98M shares derived: average of 3 quarters · filed 2025-03-20 | 173.94M shares 10-K · filed 2025-03-20 |
| 2023-09-30 | 173.98M shares 10-Q · filed 2024-11-12 | 173.92M shares derived: average of 2 quarters · filed 2024-11-12 | 173.89M shares 10-Q · filed 2024-11-12 | 157.14M shares derived: average of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | 173.86M shares 10-Q · filed 2024-08-08 | 173.84M shares 10-Q · filed 2024-08-08 | 151.52M shares derived: average of 3 quarters · filed 2024-08-08 | 136.45M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 173.83M shares 10-Q · filed 2024-05-17 | 140.36M shares derived: average of 2 quarters · filed 2024-05-17 | 123.98M shares derived: average of 3 quarters · filed 2024-05-17 | 115.72M shares derived: average of 4 quarters · filed 2024-05-17 |
| 2022-12-31 | 106.89M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 99.06M shares derived: average of 2 quarters · filed 2024-03-21 | 96.35M shares derived: average of 3 quarters · filed 2024-03-21 | 94.99M shares 10-K · filed 2024-03-21 |
| 2022-09-30 | 91.24M shares 10-K · filed 2024-03-21 | 91.09M shares derived: average of 2 quarters · filed 2024-03-21 | 91.03M shares 10-Q · filed 2023-11-09 | |
| 2022-06-30 | 90.93M shares 10-K · filed 2024-03-21 | 90.92M shares derived: average of 2 quarters · filed 2024-03-21 | ||
| 2022-03-31 | 90.91M shares 10-K · filed 2024-03-21 | |||
| 2021-12-31 | 72.08M shares 10-K · filed 2024-03-21 | |||
| 2020-12-31 | 51.56M shares 20-F · filed 2023-03-07 | |||
| 2019-12-31 | 43.07M shares 20-F · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |